Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

Comparative Real World Tumor Response in Pre-menopausal Metastatic Breast Cancer Patients Treated With Palbociclib + Aromatase Inhibitor or Aromatase Inhibitor Alone

Completed

Conditions: Metastatic Breast Cancer

Interventions: Drug: Palbociclib + aromatase inhibitor
Drug: Aromatase inhibitor

First Posted Date: 2021-08-19

Last Posted Date: 2024-10-07

Lead Sponsor: Pfizer

Target Recruit Count: 197

Registration Number: NCT05012644

Locations: 🇺🇸
Pfizer New York, New York, New York, United States

Current Treatment Outcomes in Japanese RCC Patients Treated With Avelumab Plus Axitinib as First-line Therapy: Retrospective Study (J-DART)

Completed

Conditions: Renal Cell Carcinoma

Interventions: Drug: avelumab
Drug: axitinib

First Posted Date: 2021-08-19

Last Posted Date: 2023-12-06

Lead Sponsor: Pfizer

Target Recruit Count: 48

Registration Number: NCT05012865

Locations: 🇯🇵
Osaka University Hospital, Suita-city, Osaka, Japan
🇯🇵
Jichi Medical University Saitama Medical Center, Saitama City, Saitama, Japan
🇯🇵
Kurume University Hospital, Kurume, Fukuoka, Japan

and more 9 locations

Evaluation of Protease Inhibition for COVID-19 in Standard-Risk Patients (EPIC-SR).

Phase 2

Terminated

Conditions: COVID-19

Interventions: Drug: PF-07321332
Drug: Placebo
Drug: Ritonavir

First Posted Date: 2021-08-18

Last Posted Date: 2023-08-14

Lead Sponsor: Pfizer

Target Recruit Count: 1440

Registration Number: NCT05011513

Locations: 🇺🇸
Eastern Research Inc, Hialeah, Florida, United States
🇺🇸
Premium Medical Research Corp, Miami, Florida, United States
🇺🇸
South Florida Research Center, Inc., Miami, Florida, United States

and more 217 locations

Study to Estimate the Effects of Hepatic Impairment on the Pharmacokinetics (PK) of PF-07321332

Phase 1

Completed

Conditions: Hepatic Impairment

Interventions: Drug: PF-07321332
Drug: Ritonavir

First Posted Date: 2021-08-13

Last Posted Date: 2023-09-06

Lead Sponsor: Pfizer

Target Recruit Count: 17

Registration Number: NCT05005312

Locations: 🇺🇸
Prism Research LLC dba Nucleus Network, Saint Paul, Minnesota, United States
🇺🇸
Orange County Research Center, Tustin, California, United States

A Study to Learn About the Study Medicine (Called Ontorpacept or TTI-621) Given Alone and in Combination With Doxorubicin in People With Leiomyosarcoma

Phase 2

Terminated

Conditions: Leiomyosarcoma

Interventions: Drug: Ontorpacept (TTI-621)
Drug: Doxorubicin

First Posted Date: 2021-08-09

Last Posted Date: 2024-12-11

Lead Sponsor: Pfizer

Target Recruit Count: 76

Registration Number: NCT04996004

Locations: 🇺🇸
University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
🇺🇸
Sarcoma Oncology Research Center, Santa Monica, California, United States
🇺🇸
Mayo Clinic Florida, Jacksonville, Florida, United States

and more 19 locations

Safety and Efficacy Active Drug vs. Placebo in Subjects With Asthma

Phase 1

Terminated

Conditions: Asthma

Interventions: Drug: Placebo
Drug: Zavegepant

First Posted Date: 2021-08-03

Last Posted Date: 2024-07-19

Lead Sponsor: Pfizer

Target Recruit Count: 45

Registration Number: NCT04987944

Locations: 🇨🇦
McMaster Universtiy, Hamilton, Ontario, Canada
🇨🇦
University of Saskatchewan/Royal University Hospital, Saskatoon, Saskatchewan, Canada
🇨🇦
McMaster University, Hamilton, Ontario, Canada

and more 5 locations

Real-World Outcomes of US Talazoparib-Treated Patients With Locally Advanced or Metastatic Breast Cancer

Completed

Conditions: Breast Cancer

Interventions: Drug: Talazoparib

First Posted Date: 2021-08-03

Last Posted Date: 2024-01-22

Lead Sponsor: Pfizer

Target Recruit Count: 84

Registration Number: NCT04987931

Locations: 🇺🇸
Pfizer Inc, New York, New York, United States

A Study to Evaluate GBT021601-012 Single Dose and Multiple Dose in Participants With Sickle Cell Disease (SCD)

Phase 1

Completed

Conditions: Sickle Cell Disease

Interventions: Drug: GBT021601

First Posted Date: 2021-07-30

Last Posted Date: 2024-06-10

Lead Sponsor: Pfizer

Target Recruit Count: 6

Registration Number: NCT04983264

Locations: 🇺🇸
Advanced Pharma CR, LLC, Miami, Florida, United States
🇺🇸
Children's Healthcare of Atlanta AFLAC Center, Atlanta, Georgia, United States
🇺🇸
Visionaries Clinical Research LLC, Atlanta, Georgia, United States

Korea Post Marketing Surveillance (PMS) Study of Talzenna®

Not yet recruiting

Conditions: Breast Neoplasms

Interventions: Drug: Talzenna

First Posted Date: 2021-07-29

Last Posted Date: 2025-06-12

Lead Sponsor: Pfizer

Target Recruit Count: 600

Registration Number: NCT04982848

Study to Evaluate Clinical Real World Outcomes of Lorlatinib After Alectinib in ALK-Positive NSCLC Japanese Patients

Completed

Conditions: ALK-positive Non-small-cell Lung Cancer

Interventions: Drug: Lortlatinib

First Posted Date: 2021-07-28

Last Posted Date: 2024-04-05

Lead Sponsor: Pfizer

Target Recruit Count: 51

Registration Number: NCT04979988

Locations: 🇯🇵
Juntendo University Hospital, Bunkyo-ku, Tokyo, Japan
🇯🇵
Jichi Medical University Hospital, Shimotsuke, Tochigi, Japan
🇯🇵
The Cancer Institute Hospital of JFCR, Koto-ku, Tokyo, Japan

and more 13 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy